Results 91 to 100 of about 45,696 (262)

Case Report: Pharmacokinetics of ceftazidime and avibactam during and after CRRT in an elderly patient and their associations with CNS adverse effects

Frontiers in Pharmacology
Ceftazidime/avibactam is effective for treating infections caused by multidrug-resistant gram-negative bacteria and is widely used. The pharmacokinetic data of ceftazidime and avibactam in patients receiving continuous renal replacement therapy (CRRT ...
Haiying Huang, Yun Han, Yinshan Wu, Feng Guo, Zhenwei Yu   +4 more
doaj   +1 more source

Evaluation of FilmArray Multiplex PCR Test Results in Bloodstream Infections in Oncological Patients

Journal of Clinical Laboratory Analysis, Volume 40, Issue 9, May 2026.
In this study conducted at an oncology hospital, BCID2 panel results for the rapid identification of microorganisms and resistance genes in positive blood culture samples were compared with conventional culture methods. The BCID2 panel provided faster results and showed a high correlation with traditional methods.
İpek Mumcuoğlu, Sevgi Şahin, Esra Tavukcu, Neşe İnan, Ayşe Semra Güreser, Serap Süzük Yıldız, Tuba Dal   +6 more
wiley   +1 more source

In Vitro Activities of Ceftazidime-Avibactam and Comparator Agents Against Carbapenem-resistant Enterobacterales (CRE) Collected in Africa/Middle East ATLAS Global Surveillance Program 2018-2022

International Journal of Infectious Diseases
Introduction: Avibactam (AVI) is a non-β-lactam β-lactamase inhibitor that when combined with the β-lactam ceftazidime (CAZ) has demonstrated activity against Class A, Class C and some Class D enzymes.
Dr Meredith Hackel, Dr Gregory Stone, Dr Daniel Sahm   +2 more
doaj   +1 more source

Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa [PDF]

Antimicrobial Agents and Chemotherapy, 2018
Clinical susceptibility breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa for the ceftazidime-avibactam dosage regimen of 2,000/500 mg every 8 h (q8h) by 2-h intravenous infusion (adjusted for renal function) have been established by the FDA, CLSI, and EUCAST as susceptible ...
Wright W. Nichols, Gregory G. Stone, Paul Newell, Helen Broadhurst, Angela Wardman, Merran MacPherson, Katrina Yates, Todd Riccobene, Ian A. Critchley, Shampa Das   +9 more
openaire   +2 more sources

Genomic Insights Into Carbapenem‐Resistant Klebsiella pneumoniae in Pediatric Bloodstream Infections in Zhejiang, China (2019–2024)

Journal of Clinical Laboratory Analysis, Volume 40, Issue 10, May 2026.
The primary mechanism of carbapenem resistance identified in pediatric CRKP‐BSI strains was the production of Class B metalloenzymes. We report, for the first time, an outbreak of bloodstream infections in a neonatal ward caused by the dissemination of NDM‐1‐producing ST25 K. pneumoniae.
Mingming Zhou, Xiucai Zhang, Zhenjie Chen, Chao Fang, Shixing Liu, Jintao Xia, Yining Zhao, Chenmei Zhang, Hongqiang Shen   +8 more
wiley   +1 more source

Emergence and Genomic Characterization of a Hypervirulent Klebsiella pneumoniae Isolate From a New Clone in Brazil

Microbiology and Immunology, Volume 70, Issue 5, Page 261-267, May 2026.
ABSTRACT Hypervirulent Klebsiella pneumoniae (hvKp) has emerged globally as a major public health concern, often associated with severe community‐acquired and healthcare‐associated human infections. Despite alerts from PAHO/WHO on convergent hvKp strains with multidrug resistance in Latin America, comprehensive data from Brazil, the region's largest ...
Carlos Henrique Camargo, Ana Beatriz Nascimento Costa, Amanda Yaeko Yamada, Daniel de Sena Miranda, Pedro Smith Pereira Ferraro, Andreia Rodrigues de Souza, Amanda Maria de Jesus Bertani, Karoline Rodrigues Campos, Marlon Benedito Nascimento Santos, Rafaela Mastrangelo Rissetti, Carolina Lechinski de Paula, Patrik Júnior de Lima Paz, Maria Solange Duarte Soares, Christiane Salvador, Giovanna de Pinho Pieri, Jorge Siguemassa Higa, Daniela dos Santos Souza, Márcio Garcia Ribeiro, Claudio Tavares Sacchi, Monique Ribeiro Tiba‐Casas, Geraldine Madalosso, Denise Brandao de Assis   +21 more
wiley   +1 more source

Antibiofilm activity of a chionodracine‐derived peptide by NMR‐based metabolomics of cell‐free supernatant of Acinetobacter baumannii clinical strains

FEBS Open Bio, Volume 16, Issue 4, Page 751-765, April 2026.
KHS‐Cnd peptide is able to impair biofilm formation and disaggregate mature biofilms in Acinetobacter baumannii clinical isolates. Differences in extracellular metabolites reflect changes in biofilm metabolism due to KHS‐Cnd treatment. Among the differentially represented extracellular metabolites upon KHS‐Cnd treatment, the significantly altered ...
Fernando Porcelli, Enrico Landi, Francesco Maiurano, Irene Paris, Rosanna Papa, Marco Artini, Laura Selan, Stefano Borocci, Francesco Buonocore, Esther Imperlini   +9 more
wiley   +1 more source

Molecular mechanisms responsible KPC-135-mediated resistance to ceftazidime-avibactam in ST11-K47 hypervirulent Klebsiella pneumoniae

Emerging Microbes and Infections
Ceftazidime-avibactam resistance attributable to the blaKPC-2 gene mutation is increasingly documented in clinical settings. In this study, we characterized the mechanisms leading to the development of ceftazidime-avibactam resistance in ST11-K47 ...
Qingyu Shi, S. Shen, Chengkang Tang, Li Ding, Yan Guo, Yang Yang, Shiann-Ching Wu, Renru Han, D. Yin, F. Hu   +9 more
semanticscholar   +1 more source

Ceftazidime: pharmacokinetics in young volunteers versus elderly patients and therapeutic efficacy with complicated urinary tract infections [PDF]

, 1983
Thirty-six urological patients (21 male, 15 female) aged 21 to 83 years with complicated and/or hospital-acquired urinary tract infections due to sensitive bacteria were treated with ceftazidime intravenously with a daily dose of 2 g bd over 5 to 17 days.
Kurt G. Naber, Horst Grobeckerf, Kees, Frieder K., Naber, K. G., Grobecker, H., Frieder Keesf   +5 more
core   +1 more source

Antibiotic Susceptibility of Aerobic and Facultative Anaerobic Gram-Negative Rods in Hong Kong and Implications on Usefulness of Ceftazidime-Avibactam and Ceftolozane-Tazobactam

Antibiotics
Due to the increasing resistance of aerobic and facultative anaerobic Gram-negative rods, ceftazidime-avibactam and ceftolozane-tazobactam have been launched in the market in the last few years.
Jade L. L. Teng, Elaine Chan, Tsz Tuen Li, Tsz Ying Kwan, Ka Fai Chan, Wing Ho Li, Viki W. K. Tang, Man Lung Yeung, Susanna K. P. Lau, Patrick C. Y. Woo   +9 more
doaj   +1 more source